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1  | INTRODUCTION
Women with early breast cancer must make a number of treat‐
ment decisions in conjunction with their treating team. Many of 
these decisions need patients to weigh up the advantages and dis‐
advantages of treatment options with which they are not familiar, 
in the context of their individual circumstances, values and wishes. 
Patients preferring breast conservation surgery receive adjuvant 
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Abstract
Objective: TARGIT-A	randomised	women	with	early	breast	cancer	to	receive	exter‐
nal	beam	 radiotherapy	 (EBRT)	or	 intraoperative	 radiotherapy	 (TARGIT-IORT).	This	
study aimed to identify what extra risk of recurrence patients would accept for per‐
ceived benefits and risks of different radiotherapy treatments.
Methods:  Patient preferences were determined by self‐rated trade‐off question‐
naires	 in	 two	studies:	Stage	 (1)	209	TARGIT-A	participants	 (TARGIT-IORT	n = 108, 
EBRT n = 101);	Stage	(2)	123	non-trial	patients	yet	to	receive	radiotherapy	(pre-treat‐
ment	group),	with	85	also	surveyed	post-radiotherapy.	Patients	 traded-off	 risks	of	
local	recurrence	in	preference	selection	between	TARGIT-IORT	and	EBRT.
Results: TARGIT-IORT	patients	were	more	 accepting	 of	 IORT	 than	EBRT	patients	
with	60%	accepting	the	highest	increased	risk	presented	(4%–6%)	compared	to	12%	
of	EBRT	patients,	and	2%	not	accepting	IORT	at	all	compared	to	43%	of	EBRT	pa‐
tients.	Pre-treatment	patients	were	more	accepting	of	IORT	than	post-treatment	pa‐
tients	with	23%	accepting	the	highest	increased	risk	presented	compared	to	15%	of	
post-treatment	patients,	and	15%	not	accepting	IORT	at	all	compared	to	41%	of	pre-
treatment patients.
Conclusions: Breast cancer patients yet to receive radiotherapy accept a higher re‐
currence	risk	than	the	actual	risk	found	in	TARGIT-A.	Measured	patient	preferences	
are highly influenced by experience of treatment received. This finding challenges 
the validity of post‐treatment preference studies.
K E Y WO RD S
breast cancer, external beam radiotherapy, intraoperative radiotherapy, partial breast 
irradiation, patient preferences, preference questionnaire
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radiotherapy to reduce local recurrence risk; however, external 
beam	radiotherapy	(EBRT)	is	inconvenient,	comprising	3–7	weeks	of	
daily treatments (Early Breast Cancer Trialists’ Collaborative Group, 
2005;	Smith	et	al.,	2011).	Patients	must	also	consider	the	potential	
toxicities of radiotherapy, and sometimes decide to forego radio‐
therapy	(increasing	their	risk	of	recurrence)	or	choose	mastectomy	
to avoid radiotherapy side effects and inconveniences (Boscoe et al., 
2011;	Collins	et	al.,	2009;	NSW	Department	of	Health,	2011;	Pan,	
Smith,	&	Shih,	2014;	Throckmorton	&	Esserman,	2009).
The introduction of partial breast irradiation now means that 
patients having breast conservation surgery may need to decide 
between two radiotherapy options, trading a possible increased 
risk of local recurrence for a shorter, and hence more convenient, 
radiotherapy	 treatment	 (Vaidya	et	al.,	2014;	Veronesi	et	al.,	2010).	
Targeted	 intraoperative	 radiotherapy	 (TARGIT-IORT)	 delivers	 ra‐
diation directly to the primary tumour bed, during a single session 
at	the	time	of	wide	local	excision	(WLE)	or	shortly	afterwards.	The	
TARGIT-A	trial	randomised	women	having	breast	conservation	sur‐
gery to receive either standard EBRT or intraoperative radiotherapy 
(TARGIT-IORT).	At	5	years	after	randomisation,	more	women	in	the	
TARGIT-IORT	arm	(2.1%)	than	the	EBRT	arm	(1.1%)	had	experienced	
a	local	recurrence	when	IORT	was	delivered	during	WLE	(before	pa‐
thology	results	were	available);	this	difference	was	not	statistically	
significant	 and	 was	 within	 the	 2.5%	 pre-specified	 non-inferiority	
margin. However, non‐inferiority could not be established when 
IORT	was	delivered	as	a	separate	procedure,	with	local	recurrence	
rates	of	5.4%	vs.	1.7%	for	post-pathology	 IORT	and	EBRT	respec‐
tively.	(Vaidya	et	al.,	2014,	2015).	Patients	treated	with	TARGIT-IORT	
overall had the same breast cancer mortality risk but significantly 
fewer	non-breast	cancer	deaths	than	those	treated	with	EBRT	(1.4%	
vs.	3.5%	p	=	0.0086)	(Vaidya	et	al.,	2014).	This	finding	was	supported	
by a recent meta‐analysis of partial breast irradiation techniques vs. 
whole	breast	radiotherapy	(Vaidya	et	al.,	2016).
TARGIT-IORT	has	been	shown	to	have	less	skin	toxicity	and	bet‐
ter patient‐reported outcome measures such as pain and cosmetic 
outcome	 when	 compared	 to	 EBRT	 (Keshtgar	 et	al.,	 2013;	 Vaidya	
et	al.,	2010;	Welzel	et	al.,	2013).
When	the	TARGIT-A	study	began	recruiting,	the	risk	of	local	re‐
currence	following	IORT	was	unknown,	as	was	the	level	of	risk	that	
patients might accept in order to have the more convenient single 
treatment.	We	 hypothesised	 that	 even	 if	 TARGIT-IORT	 treatment	
resulted in a higher risk of local recurrence, a proportion of patients 
may nevertheless be willing to trade a greater long‐term local recur‐
rence risk for increased short‐term convenience. We also hypoth‐
esised that demographic and social factors including employment 
status, having dependents, and living further from a treatment cen‐
tre may influence these patient preferences.
Trade‐off methodology has been validated for determining pa‐
tient	 preferences	 in	 oncology	 (Blinman,	 King,	 Norman,	 Viney,	 &	
Stockler,	2012;	Blinman	et	al.,	2010,	2011;	Duric,	Fallowfield	et	al.,	
2005;	Stiggelbout	&	de	Haes,	2001).	Respondents	are	instructed	to	
consider the positive and negative effects of a treatment together 
with	the	probabilities	of	these	effects	(Duric	&	Stockler,	2001;	Simes	
&	 Coates,	 2001).	 Subjects	 choose	 between	 competing	 treatment	
options with differing outcomes (in this case, differing risks of local 
recurrence),	and	thus,	measure	the	relative	desirability	of	one	treat‐
ment option compared with another.
Successful	 recruitment	 to	 TARGIT-A	 demonstrated	 that	 treat‐
ment‐naïve patients were willing to try a more convenient treatment 
option with an unknown level of risk. This sub‐study was designed 
to investigate what maximum increase in risk of local recurrence 
patients	would	accept	to	receive	TARGIT-IORT	in	place	of	EBRT,	in	
order	 to	 subsequently	 contextualise	 the	 TARGIT-A	 clinical	 results	
from a patient perspective.
2  | PATIENTS AND METHODS
A	 total	 of	 3,451	 patients	 from	 33	 centres	 in	 11	 countries	
were	 recruited	 into	 TARGIT-A	 between	 2000	 and	 2012	
(ISRCTN-34086741)	 (Vaidya	 et	al.,	 2010,	 2014).	 Patients	 with	
early breast cancer suitable for breast‐conserving surgery were 
randomized	to	receive	either	a	single	dose	of	TARGIT-IORT	(50	kV	
X-rays	with	 INTRABEAM(TM)	Carl	 Zeiss,	Oberkochen	Germany)	
or	 conventional	 3–7	weeks	 EBRT.	 TARGIT-IORT	 patients	 with	
high‐risk pathology as previously described also received EBRT 
(15%)	(Vaidya	et	al.,	2010).
Stage‐1 of this patient preference study was prospectively 
planned	 as	 a	 sub-study	of	 the	TARGIT-A	Trial.	 In	 2011,	 treatment	
preferences	 were	 collected	 from	 213	 TARGIT-A	 patients	 treated	
at	 least	 3	months	 previously	 as	 per	 their	 allocated	 randomisation.	
Participants	were	 reviewed	by	 their	Radiation	Oncologist	 for	 suit‐
ability for inclusion in the preference sub‐study. Patients were in‐
eligible if the study would be considered an unwelcome imposition 
based	on	social,	psychological	or	other	circumstances	(Figure	1).
From	2012	to	2014	preferences	were	collected	 from	a	 further	
123	usual-care	patients	recently	diagnosed	with	breast	cancer	but	
yet	to	receive	radiotherapy	(Stage-2).	Stage-2	(pre-treatment	group)	
was developed as a follow‐up study to test additional hypotheses 
informed	by	Stage-1.	In	2015,	Stage-2	participants	who	had	initially	
been surveyed pre‐treatment, and who had not declined further 
contact, were mailed a second “post‐treatment” questionnaire. 
Human research ethics approvals were obtained for all studies and 
all participants provided written informed consent.
2.1 | Instruments and evaluations
2.1.1 | Stage‐1, TARGIT‐A group
TARGIT-A	participants	were	mailed	an	invitation	letter	with	an	opt-
out	card.	Patient	preference,	demographics	and	the	Patient	Disease	
And	Treatment	Assessment	 (Patient	DATA)	questionnaires	utilised	
in previous preference studies were adapted for this study and were 
mailed	 to	 patients	 who	 did	 not	 opt	 out	 (Supporting	 Information	
Appendices	S1–S3)	(Blinman	et	al.,	2010;	Duric,	Stockler,	et	al.,	2005;	
Simes	&	Coates,	2001).	The	questionnaire	method	of	eliciting	patient	
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preferences has been validated through prospective comparison to 
scripted	face-to-face	methodology	(Blinman	et	al.,	2010).
The preference questionnaire was used to determine the largest 
5‐years recurrence risk that women considered acceptable in return 
for	the	shorter	duration	and	altered	toxicity	profile	of	TARGIT-IORT.	
Participants were asked to imagine they knew what their risk of local 
recurrence would be with conventional EBRT. They were then asked 
to determine the maximum increased risk of local recurrence they 
would	accept	 in	order	 to	receive	TARGIT-IORT.	Risk	of	 recurrence	
of	EBRT	was	 represented	as	3%	 in	Question	1,	6%	 in	Question	2,	
then	as	3/100	in	Question	3	and	6/100	in	Question	4	(Supporting	
Information	Appendix	S1).
Acknowledging	that	an	event	such	as	treatment	for	breast	cancer	
may alter some variable patient characteristics, such as work status, 
where appropriate the demographics questionnaire was answered 
for three separate time points: “before breast cancer,” “during breast 
cancer treatment” and “now” (being the time of questionnaire com‐
pletion)	(Supporting	Information	Appendix	S2).
The	patient	DATA	form	consists	of	22	questions	which	are	scored	
from	0	 (no	 trouble	at	all)	 to	10	 (Worst	 Imaginable)	by	participants	
to indicate the extent to which different aspects of their treatment 
troubled them. Participants were instructed to recall symptoms 
during radiotherapy treatment. The scores are grouped as shown in 
Supporting	Information	Appendix	S3.
2.1.2 | Stage‐2, pre‐treatment group
Potential participants were identified during multidisciplinary team 
meetings, and the study was discussed by the attending surgeon. 
Interested	patients	were	telephoned	by	the	study	coordinator	who	
then mailed out questionnaires to those who agreed to participate. 
The preference questionnaire was modified slightly for the pre‐
treatment	 setting	 (Supporting	 Information	 Appendix	 S4).	 Stage-1	
participants had demonstrated a preference for risk presented as a 
proportion; hence, the questions represented as percentages were 
removed. This allowed an alternative preference scenario to be ex‐
amined:	 TARGIT-IORT	 being	 delivered	 either	 during	WLE,	 or	 as	 a	
second	procedure.	Demographics	were	also	collected.	Participants	
who agreed to further contact were mailed a second questionnaire 
1 year later, to capture preferences “post‐treatment.”
F I G U R E  1  CONSORT	diagram—
Stage-1.	IORT:	intra-operative	
radiotherapy; EBRT: external beam 
radiotherapy;	NESB:	non-English	speaking	
background. *Missing data: questionnaires 
were returned with key data missing, and 
attempts to contact patients to retrieve 
missing data were unsuccessful
4 of 10  |     CORICA et Al.
2.2 | Analysis and interpretation
Statistical significance was set at p < 0.01 to account for mul‐
tiple	 comparisons	 (Bland	 &	 Altman,	 1995;	 Bottomley	 et	al.,	
2004).	 IBM-SPSS-V23	 (SPSS	 Inc.,	 Chicago,	 IL,	 USA)	 was	 used	
for all analyses. The Kappa statistic was used to determine reli‐
ability between percentage and proportion based questions and 
between the two baseline levels of recurrence risk presented. 
Kappa scores were interpreted based on levels of agreement de‐
scribed	by	Landis	and	Koch;	<0	Poor,	0.0–0.20	Slight,	0.21–0.40	
Fair,	 0.41–0.60	 Moderate,	 0.61–0.80	 Substantial,	 0.81–1.00	
Almost	perfect	(Landis	&	Koch,	1977).	Non-parametric	Wilcoxon	
Signed-Rank	(paired)	tests	were	used	to	test	differences	between	
responses	for	TARGIT-IORT	as	a	separate	procedure	vs.	TARGIT-
IORT	delivered	during	WLE,	and	between	the	pre-treatment	vs.	
post‐treatment preference setting. Multivariate and univariate 
Poisson regression was utilised to test potential predictors of pa‐
tient preference.
3  | RESULTS
A	 total	 of	 336	 consecutive	 TARGIT-A	 participants	 were	 reviewed	
for	 suitability,	 and	exclusions	are	 shown	 in	Figure	1.	Two	hundred	
and thirteen evaluable responses were received; 108 had received 
TARGIT-IORT,	101	had	received	EBRT	and	four	had	received	both	
TARGIT-IORT	and	EBRT.
A	 total	 of	 151	 standard	 care	 patients	 were	 invited	 to	 partici‐
pate	 in	 Stage-2	 (pre-treatment	 preference	 study),	with	 123	 evalu‐
able questionnaires received. The “post‐treatment” questionnaire 
was	mailed	 to	119	of	 the	123	 initial	participants	with	85	 returned	
(Figure	2).
Demographics	were	similar	across	all	groups,	although	Stage-2	
patients were slightly younger, had more child dependents, and 
higher levels of education and employment than Stage‐1 partic‐
ipants	 (Table	1).	 These	 factors	were	 considered	 in	 single	 and	mul‐
tivariate	 analysis	 of	 patient	 preference	 (Supporting	 Information	
Appendix	S5).
F I G U R E  2  CONSORT	diagram—
Stage‐2
STAGE 2 
PRE-TREATMENT GROUP 
Patients invited 
n = 151 
Questionnaires 
returned 
n = 127 (84%) 
Unreturned 
questionnaires 
n = 24 (16%) 
Reasons for non-return 
• Unknown: 10 (42%) 
• Prefer not to: 8 (33%) 
• Too complex: 4 (17%) 
• Too unwell: 2 (8%) 
Included 
n = 123 (97%)
Excluded 
n = 4 (3%) 
• Previously received       
radiotherapy: 2 (50%) 
• Post Radiation Oncology 
review: 2 (50%) 
Post-treatment sub-group 
Invited for second questionnaire 
n = 119 (97%)
Questionnaires 
returned 
n = 85 (71%) 
Unreturned 
questionnaires 
n = 34 (28%) 
Included 
n = 85 (100%) 
Reasons for non-return 
• Unknown: 28 (82%) 
• Prefer not to: 6 (18%) 
1 had died 
3 declined further 
participation 
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TARGIT-IORT	patients	recalled	fewer	symptom	concerns	during	
treatment	 than	EBRT	patients	 across	 all	 Patient	DATA	 form	ques‐
tions. Significant (p	≤	0.01)	 differences	were	 found	 in	 seven	of	22	
questions,	with	TARGIT-IORT	patients	recalling	fewer	problems	with	
fatigue, energy levels, skin problems, breast sensitivity, treatment 
convenience, coping with treatment and being able to do the things 
they	wanted	 (Supporting	 Information	Appendix	S6).	These	 factors	
were considered in single and multivariate analysis of patient prefer‐
ence	(Supporting	Information	Appendix	S5).
3.1 | Preference results
Figure	3	 illustrates	averaged	preference	scores	 in	 four	ordinal	cat‐
egories	for	each	patient	group.	In	Stage-1,	patients	who	had	received	
TARGIT-IORT	through	random	assignment	were	less	risk-averse	than	
those	who	had	received	EBRT	with	60%	vs.	12%	accepting	IORT	at	
the	4%–6%	increased	risk	level,	31%	vs.	26%	at	the	1%–3%	increased	
level,	7%	vs.	20%	if	equivalent	to	EBRT	and	2%	vs.	43%	not	finding	
it	acceptable	at	all	(“never”).	In	Stage-2,	pre-treatment	patients	were	
less	risk-averse	than	post-treatment	patients	with	23%	vs.	15%	ac‐
cepting	IORT	at	the	4%–6%	increased	risk	level,	43%	vs.	26%	at	the	
1%–3%	increased	level,	20%	vs.	18%	if	equivalent	to	EBRT	and	15%	
vs.	41%	not	finding	it	acceptable	at	all	(“never”)	(Figure	3).
With	23%	of	the	Stage-2	pre-treatment	respondents	accepting	
TARGIT-IORT	 at	 the	 4%–6%	 increased	 risk,	 they	 were	 more	 risk-
averse	than	Stage-1	TARGIT-IORT	patients	(60%)	but	less	risk-averse	
than the Stage‐1 patients who had completed EBRT following ran‐
dom	assignment	(12%).
However, after Stage‐2 participants had completed treatment, 
their responses changed to more closely approximate Stage‐1 post‐
EBRT	 responses	 (15%	 and	 12%	 accepting	 4%–6%	 increased	 risk	
F I G U R E  3  Averaged	maximum	acceptable	increased	risk.	IORT:	
Patients	received	TARGIT-IORT	on	the	TARGIT-A	Trial	(Stage-1);	
EBRT:	Patients	received	EBRT	on	the	TARGIT-A	Trial	(Stage-1);	
Pre‐Rx: Patients completed preference questionnaire prior to any 
radiotherapy	(Stage-2);	Post-Rx:	Patients	completed	the	preference	
questionnaire	after	radiotherapy	(Stage-2);	High	Risk:	Would	accept	
IORT	if	local	recurrence	was	4%–6%	higher	than	EBRT;	Low	Risk:	
Would	accept	IORT	if	local	recurrence	was	1%–3%	higher	than	
EBRT;	Equivalent:	Would	only	accept	IORT	if	local	recurrence	was	
equivalent	to	EBRT;	Never:	Would	never	accept	IORT
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respectively).	 Overall	 acceptance	 (those	 not	 selecting	 “never”)	 of	
TARGIT-IORT	 was	 98%	 for	 the	 Stage-1	 post-TARGIT-IORT	 group,	
58%	 for	 the	 Stage-1	 post-EBRT	 group,	 86%	 for	 the	 Stage-2	 pre-
treatment	group	and	59%	for	the	Stage-2	post-treatment	group.
The only significant characteristic impacting preference in 
Stage-1	was	the	treatment	patients	had	received	on	the	TARGIT-A	
Trial	(TARGIT-IORT	or	EBRT;	p	=	<0.001,	mean	difference	2.5).	This	
remained unchanged when controlling for other potential drivers of 
treatment preference.
In	the	pre-treatment	Stage-2	participants,	no	significant	relation‐
ship was observed between preference outcomes and demograph‐
ics. Post‐treatment, having child dependents was a weak predictor 
for	 greater	 acceptance	 of	 TARGIT-IORT	 as	 a	 separate	 procedure	
(p	=	0.006)	 in	multivariate	analysis,	but	 this	was	not	significant	 for	
IORT	during	WLE	 (p	=	0.019).	 Stage-2	patients	were	more	 accept‐
ing	of	TARGIT-IORT	pre-treatment	 than	 they	were	post-treatment	
(Wilcoxon signed‐rank test p <	0.001).
3.2 | Analyses specific to the TARGIT‐A group 
(Stage‐1)
Twenty‐six percentage of participants preferred risk represented as 
a	percentage,	56%	preferred	a	proportion	out	of	100%	and	15%	had	
no preference.
Multivariate and univariate analysis revealed no significant dif‐
ferences in patient characteristics over the different time points 
used in the demographics questionnaire (“before breast cancer,” 
“during	treatment”	and	“now”),	hence	only	the	“now”	data	were	used	
in the final analysis.
3.3 | Analyses specific to the pre‐treatment group 
(Stage 2)
Table 2 shows patient, tumour and treatment characteristics of 
Stage	2	participants	with	60%	meeting	the	“low	risk”	criteria	used	
for	TARGIT-A	in	Australia	(<2	cm	tumours,	Grade	1–2,	clear	margins,	
hormone	receptor	positive,	node	negative,	ductal	(not	lobular),	neg‐
ative for extensive intraductal component or lymphovascular inva‐
sion)	(Vaidya	et	al.,	2010).	82%	of	Stage-2	participants	subsequently	
received	 conventional	 6-week	 EBRT,	 15%	 received	 hypofraction‐
ated	 (3–4	week)	 EBRT	 and	 2%	 received	 TARGIT-IORT.	 If	 all	 treat‐
ment	modalities	offered	equivalent	outcomes,	13%	of	pre-treatment	
patients	chose	EBRT,	25%	chose	TARGIT-IORT	as	a	separate	proce‐
dure	 and	62%	 chose	 TARGIT-IORT	during	WLE	 as	 their	 preferred	
option	 (Figure	4).	After	 the	patients	had	completed	 treatment,	 ac‐
ceptability	of	EBRT	increased	to	29%	but	decreased	for	the	TARGIT-
IORT	options	to	15%	for	TARGIT-IORT	separate	to	WLE	and	55%	for	
TARGIT-IORT	during	WLE	(paired	t test p	=	0.013,	mean	difference	
0.24).	Overall,	 87%	of	patients	who	had	not	 yet	 had	 radiotherapy	
accepted	TARGIT-IORT	over	EBRT,	and	this	proportion	decreased	to	
70%	after	patients	had	received	treatment.
There was no difference in preferences when patients were pre‐
sented	with	alternative	scenarios	of	IORT	as	a	separate	procedure	
or	during	WLE	at	either	level	of	baseline	recurrence	risk	(Wilcoxon	
signed‐rank test p	=	0.338	 and	 0.335	 respectively)	 for	 pre-treat‐
ment or post‐treatment groups (p	=	0.216	and	0.624	respectively).
Participants could opt to leave free text comments on the final 
page.	This	data	are	described	in	Supporting	Information	Appendix	S7.
4  | DISCUSSION AND CONCLUSION
Patient preference studies are increasingly recognised as an impor‐
tant secondary, and in some cases primary, outcome in health care 
research. This preference study utilised validated questionnaire 
methodology in two sequential studies, each with two patient co‐
horts; Stage‐1 included patients who had already received either 
TARGIT-IORT	or	EBRT	on	the	TARGIT-A	trial	and	Stage-2	included	
breast cancer patients yet to receive radiotherapy, most of whom 
were surveyed again post‐treatment.
The most striking finding of this research was the discovery 
that preferences elicited in the post‐treatment setting yield very 
different results to those elicited in the pre‐treatment setting. This 
TA B L E  2   Tumour and treatment characteristics of pre‐
treatment group
Pre‐treatment 
questionnaire
Post‐treatment 
questionnaire
n % n %
TARGIT-A	eligiblea
Yes 74 60 50 59
No 49 40 35 41
Pathology
Grade 1 or 2 111 90 75 88
Unifocal 120 98 82 96
≥	50	years 114 93 78 92
≤2	cm 108 88 75 88
No	extensive	intraductal	
component	(EIC-ve)
109 89 77 91
No	lymphovascular	
invasion	(LVI-ve)
116 94 82 96
Hormone receptor 
positive
116 94 81 95
Radiotherapy receivedb
EBRT	(6	weeks) – – 70 82
EBRT	(3–4	weeks) – – 13 15
IORT – – 2 2
Notes.	 EBRT:	 external	 beam	 radiotherapy;	 IORT:	 intraoperative	
radiotherapy.
aPatient and tumour characteristics were within the eligibility criteria for 
TARGIT-A	in	Australia	(<20	cm	tumours,	Grade	1–2,	clear	margins,	hor‐
mone	receptor	positive,	node	negative,	ductal	(not	lobular),	negative	for	
extensive	 intraductal	 component	 or	 lymphovascular	 invasion).	 bRadio‐
therapy details were only collected from patients providing a post‐treat‐
ment questionnaire. 
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study, in which preferences were first elicited from patients who 
had completed treatment with one of two radiotherapy modali‐
ties to which they had been randomly assigned, demonstrated that 
the most important determinant of treatment preference was the 
treatment	 already	 experienced	 by	 that	 patient.	 Despite	 patients	
having	entered	the	trial	accepting	a	50%	chance	of	randomisation	
to either radiotherapy technique, those who had been randomised 
to	 TARGIT-IORT	 strongly	 favoured	 the	 treatment	 they	 had	 re‐
ceived, even at a hypothetical increased risk of recurrence com‐
pared	to	the	EBRT	group.	Furthermore,	43%	of	patients	who	had	
been randomised to and received EBRT indicated they would not 
accept	TARGIT-IORT	at	all.	The	only	plausible	explanation	for	this,	
in patients with similar characteristics who had provided informed 
consent to randomisation to either treatment, is that patients were 
justifying the treatment they had received, therefore indirectly 
justifying their decision to participate in the randomised trial, thus 
potentially	avoiding	decisional	regret.	Optional	comments	made	by	
Stage‐1 participants demonstrated that as their experience with 
the treatment they had received on the randomised study was ac‐
ceptable to them, they were biased towards that treatment when 
completing the preference questionnaire. There were very few 
comments suggesting that the recalled toxicities of treatment im‐
pacted	treatment	preferences.	Analysis	of	the	Patient	DATA	form	
confirmed	 this;	 despite	 TARGIT-IORT	 patients	 reporting	 signifi‐
cantly fewer treatment side effects, none of these factors were 
determinants of preferences after treatment. Time since treatment 
did not impact preference results in Stage‐1; however, treatment 
had	 been	 completed	 4–85	months	 prior	 to	 completion	 of	 the	
Patient	DATA	form	which	 is	 likely	 to	have	 introduced	some	 level	
of recall bias.
This preference study originally set out to identify what hypo‐
thetical level of increased risk of local recurrence patients would 
accept in order to choose a new, more convenient treatment op‐
tion	 (TARGIT-IORT)	 over	 conventional	 EBRT.	 Preferences	 varied	
across all four patient groups, with the least risk‐averse group being 
those	who	had	received	TARGIT-IORT	on	the	TARGIT-A	study	(98%	
overall	acceptance	of	IORT,	and	60%	accepting	it	at	the	highest	in‐
creased	risk	presented	which	was	4%–6%),	and	the	most	risk-averse	
groups	 being	 the	 TARGIT-A	 EBRT	 group	 and	 the	 post-treatment	
Stage-2	 participants	 (27%–29%	 overall	 acceptance	 of	 IORT,	 with	
12%–15%	accepting	 it	 at	 the	highest	 risk	presented-4%–6%).	The	
Stage‐2 pre‐treatment group demonstrated intermediate prefer‐
ences,	with	85%	overall	acceptance	of	IORT	and	23%	accepting	it	
at	the	highest	risk	presented,	4%–6%	increase	in	local	recurrence.	
These preference results showed that around a third of patients 
were	willing	to	accept	TARGIT-IORT	at	a	higher	risk	than	that	which	
was	 observed	 in	 the	 TARGIT-A	 trial,	 which	 found	 non-significant	
absolute	increases	in	risk	of	recurrence	of	1%	in	the	group	having	
IORT	during	WLE	and	3.7%	in	the	group	having	IORT	as	second	sep‐
arate	procedure.	Although	IORT	during	WLE	is	the	recommended	
approach, it is not always feasible. These results suggest that some 
women, at least before they have experienced treatment, may ac‐
cept	a	risk	of	recurrence	in	keeping	with	the	results	of	TARGIT-A	in	
order	to	receive	IORT	as	a	separate	procedure,	if	immediate	IORT	
is not possible. The results of this study therefore provide a further 
discussion point for providers when considering obstacles to radio‐
therapy access, especially for patients in rural and remote areas. 
If	health	professionals	and	informed	patients	accept	the	small	ad‐
ditional risk of local recurrence for a more convenient treatment 
schedule, then it may be considered an option for suitable patients, 
and would be preferable to forgoing radiotherapy due to the incon‐
venience of EBRT.
That treatment experience would be the only important determi‐
nant of retrospective patient preference in a randomised population 
was not anticipated when this research began. The only previous 
preference study of adjuvant radiotherapy following breast‐con‐
serving surgery, and indeed most previous preferences research, 
had been conducted following more homogeneous treatment 
(Duric,	Stockler,	et	al.,	2005;	Hayman,	Fairclough,	Harris,	&	Weeks,	
1997).	 The	 methodology	 and	 timing	 of	 administration	 of	 Stage	 1	
of this study was therefore based on these prior validated studies; 
furthermore, the validity of the paper‐based questionnaire method‐
ology	had	also	been	established	 (Blinman	et	al.,	2010).	Our	results	
from Stage 1 of the study are the first to question the validity of elic‐
iting preferences post‐treatment and to identify the potential role of 
avoidance of decisional regret. There was no indication that other 
aspects of the discrete choice methodology, or the use of a paper‐
based questionnaire, were less valid in this population than in prior 
studies.	A	concurrent	study	of	patient	preferences	for	TARGIT-IORT	
in	 the	USA	reported	 that	91%	of	patients	 found	TARGIT-IORT	ac‐
ceptable,	with	a	median	increase	in	acceptable	risk	of	2.3%	(Alvarado	
et	al.,	2014).	This	is	comparable	to	the	“low	increased	risk”	category	
(a	 1%–3%	 increase)	 in	 the	present	 study	which	was	 acceptable	 to	
91%	of	 the	TARGIT-IORT	group,	38%	of	 the	TARGIT-EBRT	group,	
66%	 of	 the	 pre-treatment	 group	 and	 41%	 of	 the	 post-treatment	
group. However, in that study, combined results were reported from 
21	 pre-treatment	 and	 60	 post-treatment	 patients.	 Results	 from	
our larger study question the appropriateness of combining these 
groups.
Another	 study	 investigating	 preferences	 for	 adjuvant	 chemo‐
therapy	 (ACT)	 after	 early	 breast	 cancer	 showed	 stability	 of	 pref‐
erences before and after treatment; however importantly, these 
F I G U R E  4  Preferred	treatment	option—Stage-2.	EBRT:	external	
beam	radiotherapy;	IORT:	intraoperative	radiotherapy;	WLE:	wide	
local excision
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patients had selected their treatment, rather than being randomised 
(Jansen	et	al.,	2001).
Our	results	challenge	the	utility	of	eliciting	patient	preferences	
post‐treatment in a randomised controlled trial. This population 
does not represent the knowledge base of treatment‐naïve patients, 
and results may be significantly biased by the avoidance of decision 
regret, albeit an unconscious bias, in patients who have completed 
treatment. This interpretation is supported by a recent preference 
study in patients with endometrial cancer who were randomised to 
receive	ACT	vs.	no	ACT.	Preferences	were	elicited	both	after	rando‐
misation	but	before	treatment,	and	9	months	later	(after	treatment)	
(Blinman	et	al.,	2016).	Findings	were	similar	 to	our	 study,	with	pa‐
tients	who	 had	 received	ACT	 requiring	 smaller	 benefits	 to	 accept	
ACT	 than	 those	who	 did	 not	 receive	 it,	 and	 less	 benefit	 required	
post‐treatment than pre‐treatment. These results suggest that the 
actual	 experience	 of	 ACT	 treatment	 may	 have	 been	 better	 than	
anticipated, or that preferences justified participation in the ran‐
domised trial and avoided decision regret. These results also explain 
the surprising finding that some women will accept almost zero ben‐
efit	 for	ACT	 for	early	breast	 cancer	when	preferences	are	elicited	
after	treatment	(Duric	&	Stockler,	2001;	Duric,	Stockler,	et	al.,	2005;	
Vaz-Luis	et	al.,	2017).
4.1 | CONCLUSION
In	terms	of	the	primary	goal	of	this	research,	we	found	that	women	
who had yet to receive radiotherapy for early breast cancer indi‐
cated	that	TARGIT-IORT	was	an	acceptable	treatment	option,	with	
the majority of patients also willing to accept a higher risk of recur‐
rence in order to have the more convenient treatment option. The 
most striking finding of this research was however the incidental 
discovery that preferences elicited post‐treatment are significantly 
biased by the experience of treatment received. Preferences elic‐
ited post‐treatment appear instead to be an indirect method of 
eliciting patient satisfaction of treatment already received, and 
therefore offer a biased account of preference, rather than a con‐
sumer perspective of all potential treatments on offer. The results 
of our study strongly challenge the use and interpretation (and thus 
the	validity)	of	post-treatment	preference	studies.	We	recommend	
that	both	qualitative	(Duric,	Fallowfield,	et	al.,	2005;	Jansen	et	al.,	
2001)	 and	 quantitative	 pre-treatment	 patient	 preference	 studies	
are utilised in future research, together with post‐treatment pref‐
erences and measurements of treatment satisfaction and/or deci‐
sion regret.
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